3-chloro-4,5-dimethylisoxazole | 17281-07-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 3-chloro-4,5-dimethylisoxazole
• 英文别名: 3-Chloro-4,5-dimethyl-1,2-oxazole
• CAS: 17281-07-1
• 化学式: C₅H₆ClNO
• mdl: MFCD18449686
• 分子量: 131.562
• InChiKey: LZPSBSOLLSDEIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4,5-dimethylisoxazole 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 sodium ethanolate 作用下， 反应 32.0h， 生成 (RS)-2-amino-3-(3-chloro-5-methyl-4-isoxazolyl)propionic acid hydrochloride
  参考文献：
  名称：

  Synthesis and pharmacology of (RS)-2-amino-3-(3-hydroxy-5-trifluoromethyl-4-isoxazolyl)propionic acid, a potent AMPA receptor agonist

  摘要：

  Three isoxazole bioisosteres of glutamic acid derived from the specific AMPA receptor agonist (RS)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) were synthesized and tested electrophysiologically and in different receptor binding systems. (RS)-2-Amino-3-(3-hydroxy-5-trifluoromethyl-4-isoxazolyl)propionic acid (trifluoro-AMPA, 8) showed more potent agonist activity (EC50 2.3 muM) and lower affinity (IC50 0.08 muM) for AMPA receptors than AMPA itself (EC, 3.5 muM and IC50 0.04 muM, respectively). Like AMPA, trifluoro-AMPA (8) did not bind significantly to N-methyl-D-aspartic acid (NMDA) receptor sites, but trifluoro-AMPA (8) was more potent as an inhibitor of [H-3]kainic acid ([H-3]KAIN) binding (IC50 7.1 muM) than AMPA (IC50 32 muM). (RS)-2-Amino-3-(3-chloro-5-methyl-4-isoxazolyl)propionic acid (14), the 3-chloro analogue of AMPA, and the isomeric compound (RS)-2-amino-3-(3-chloro-4-methyl-5-isoxazolyl)propionic acid (15), did not show significant neuroexcitatory effects at or affinities for AMPA, NMDA, or KAIN receptor sites.

  DOI：

  10.1016/0223-5234(92)90181-y
• 作为产物：
  描述：

  3-chloro-2,4,5-trimethyl-1,2-oxazol-2-ium;chloride;hydrochloride 以35%的产率得到
  参考文献：
  名称：

  TOMITA K.; SUGAI S.; KOBAYASHI T.; MURAKAMI T., CHEM. AND PHARM. BULL., 1979, 27 NO 10, 2398-2404

  摘要：

  DOI：

文献信息

• [EN] THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN, AND CHECKPOINT INHIBITORS<br/>[FR] THIÉNOPYRANONES ET FURANOPYRANONES EN TANT QU'INHIBITEURS DE KINASE, DE BROMODOMAINE ET DE POINTS DE CONTRÔLE
  申请人：SIGNALRX PHARMACEUTICALS INC

  公开号：WO2018140730A1

  公开（公告）日：2018-08-02

  The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of cell cycle checkpoint targets CDKs, and/or PI3 kinase, and/or bromodomain protein binding to substrates, comprising the administration of a compound(s) of Formula 1 -Vl (or pharmaceutically acceptable salts thereof) as defined herein.

  这项发明涉及化合物和治疗疾病的方法，包括但不限于癌症、非癌性增生性疾病、败血症、自身免疫疾病、病毒感染、动脉粥样硬化、1型或2型糖尿病、肥胖症、炎症性疾病或通过通过抑制细胞周期检查点靶点CDKs、和/或PI3激酶、和/或溴结构域蛋白结合到底物来调节生物过程，包括根据本文所定义的将化合物的给药作为公式1-Vl（或其药学上可接受的盐）的组成部分。
• NOVEL COMPOUNDS
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US20170340611A1

  公开（公告）日：2017-11-30

  Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.

  本文定义的式(I)的吡唑酮衍生物具有人类中性粒细胞弹性蛋白酶抑制性质，并可用于治疗与HNE有关的疾病或症状。
• HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME
  申请人：Jachmann Markus

  公开号：US20100137362A1

  公开（公告）日：2010-06-03

  A hydrazide compound represented by the formula (I), an N-oxide thereof or suitable salt thereof: has excellent pesticidal activity.

  一种由式(I)表示的腙酰肼类化合物，其N-氧化物或适当的盐：具有优异的杀虫活性。
• Pyrazolone compounds having human neutrophil elastase inhibitory properties
  申请人：CHIESI FARMACEUTICI S.P.A.

  公开号：US10172830B2

  公开（公告）日：2019-01-08

  Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.

  本文定义的式 (I) 吡唑酮衍生物具有人类中性粒细胞弹性蛋白酶抑制特性，可用于治疗与 HNE 有关的疾病或病症。
• Tomita,K. et al., Chemical and pharmaceutical bulletin, 1979, vol. 27, # 10, p. 2398 - 2404
  作者：Tomita,K. et al.

  DOI：——

  日期：——